Logo

Aurora Biosciences Licenses Technology From Xenometrix

Dec 18, 1998
Premium

BOULDER, Colo.--Aurora Biosciences of San Diego has gained access to the gene expression profiling technology for which Xenometrix here received a European patent in January. Xenometrix's non-exclusive license covers gene expression profiling utilizing methods other than high-density oligonucleotide microarrays.

Aurora also announced that Paul England has been promoted from vice-president discovery operations to senior vice-president research. England joined Aurora in February after 13 years in pharmaceutical research at SmithKline Beecham.

Filed under

Informatics
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.